Fig. 9.

OGT dependent release of the differentiation blockage upon treatment with dronabinol in AML leukemia cells. (a) Representative analysis of in vivo OGT expression in a patient prior to and two months after start of treatment with dronabinol. (b) OGT expression, as assessed by flow cytometry, in a patient sample taken at diagnosis and treated with dronabinol ex vivo. (c) FSC/SSC-based flow cytometry assay to determine the viable population after treatment of pt's native leukemic blasts with dronabinol for 48 h ex vivo. OGT-interference demonstrates effective rescue of the patient sample treated with the highest tested dose at 80 μM. Statistical significance at p < 0.05 (one-way ANOVA), n = 3.